Stock Price & Analysis

The S1 support level for BRNS Stock is $0.98 ,The R1 resistant level for BRNS Stock is $1.16.

As of the end of day on 2025-02-21, the price of BRNS Stock was $1.05.

The target price for BRNS Stock according to analyst rating is 4.50, with the highest price target at 6.00 and the lowest at 3.00. Analysts have a Moderate Buy rating on BRNS Stock overall.

The market cap of BRNS is $40.2M.

Barinthus Biotherapeutics plc, formerly Vaccitech plc, is a clinical-stage biopharmaceutical company. It is focused on developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Its four platform technologies include ChAdOx, MVA, SNAP-TI, and SNAP-CI. It is advancing a pipeline of five product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer, and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer.

BRNS has a total of 130 employees.